Research programme: brain cancer stem cell therapeutics - Loma/Neuralstem

Drug Profile

Research programme: brain cancer stem cell therapeutics - Loma/Neuralstem

Alternative Names: HNSC - Neuralstem; NSI 566 - Loma/Neuralstem; NSI-566 - Glioblastoma

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuralstem
  • Developer Loma Linda University Medical Center; Neuralstem
  • Class Stem cell therapies
  • Mechanism of Action Angiogenesis inhibitors; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glioblastoma in USA (Intracerebral, Injection)
  • 13 May 2013 Preclinical development in Glioblastoma is ongoing in USA
  • 03 Aug 2011 Preclinical trials in Brain cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top